SPRB (Spruce Biosciences) Short Interest


SPRB Spruce Biosciences Inc SPRB
35 GF Score
Price $51.20
GF Value $4.08
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Spruce Biosciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

SPRB vs HURA, AGEN, CRBP: Short Interest Comparison

For the Biotechnology subindustry, Spruce Biosciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spruce Biosciences Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spruce Biosciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Spruce Biosciences's Short Interest falls into.


SPRB
35GF Score
Spruce Biosciences Inc SPRB
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Spruce Biosciences (SPRB) Overvalued in 2026?

Based on GuruFocus' analysis, Spruce Biosciences stock appears to be overvalued. The current stock price of $51.20 is trading 1154.9% above its estimated GF Value™ of $4.08. GuruFocus considers Spruce Biosciences to be Significantly Overvalued.

Key valuation signals for SPRB:

  • Short Interest:
  • GF Value™: $4.08 vs. price of $51.20 (1154.9% above fair value)
  • GF Score™: 35/100 with 1 warning sign

No single metric tells the full story. See the SPRB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spruce Biosciences Business Description

Address 611 Gateway Boulevard, Suite 740, South San Francisco, CA, USA, 94080
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
35GF Score

Get the complete analysis for SPRB

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$51.20
Price
$4.08
GF Value